Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
复制标题
DOI：
10.1038/s41391-020-00271-7
复制
发表时间：
2021-03
影响因子：
4.8
通讯作者：
Taplin ME
中科院分区：
文献类型：
--
作者：
McKay RR;Silver R;Bhak RH;Korves C;Cheng M;Appukkuttan S;Simmons SJ;Duh MS;Taplin ME
目前尚不存在抗去势转移性前列腺癌(MCRPC)的Re-223和化疗的最佳排序指南。这项研究在学术临床环境中评估了用Re-223治疗的mCRPC患者的治疗模式和总存活率(OS)。对以骨转移为主的mCRPC患者进行了一项回顾性研究，患者接受了Re-223治疗。对2013年至2018年接受Re-223化疗前和化疗后的患者的治疗模式进行了评估。用Kaplan-Meier中位数和95%可信区间检查OS。共治疗2 2 0例，其中化疗前治疗83例，化疗后治疗73例。在化疗前和化疗后的队列中，平均每位患者分别注射了5.3Re和4.3Re(p <； 0.001)。在Re-223之前或之后给予化疗的化疗周期数相似。化疗前和化疗后mCRPC治疗的平均线分别为3和5(p <； 0.001)。41.8%的患者接受Re-223联合另一种mCRPC治疗，通常为醋酸阿比特龙(43.5%)或苯扎鲁胺(52.2%)。大多数人在Re-223治疗期间接受了联合治疗；20.7%的人在Re-223开始治疗后开始使用另一种药物；20.7%的人在已经确定的治疗期间开始使用Re-223。首次接受mCRPC治疗的患者化疗前中位OS为39.4个月(95%CI为33.0，48.8)，化疗后为37.4个月(95%CI为32.0，43.5)(Re-223联合治疗患者为35.2个月[95%CI为27.9，43.3]，Re-223联合治疗为32.0个月[95%CI为26.9，36.0]。这项对使用Re-223治疗的患者的回顾分析表明，化疗前使用Re-223可以增加完成Re-223治疗的可能性。在化疗前或化疗后给予Re-223，并进行或不进行联合治疗，均未导致OS显著差异。需要进一步的研究来确定mCRPC在现代的最佳测序策略。
Guidelines for optimal sequencing of radium-223 and chemotherapy for metastatic castration resistant prostate cancer (mCRPC) do not exist. This study evaluated treatment patterns and overall survival (OS) among patients with mCRPC treated with radium-223 in an academic clinical setting. A retrospective study was conducted of bone metastases-predominant mCRPC patients treated with radium-223. Treatment patterns from 2013 to 2018 were evaluated in patients treated with radium-223 pre- vs. post-chemotherapy. OS was examined using Kaplan–Meier medians and 95% confidence intervals. In total, 220 patients were treated with radium-223 (64 pre-chemotherapy, 83 post-chemotherapy, 73 no chemotherapy). Mean radium-223 injections per patient was 5.3 and 4.3 in the pre- vs. post-chemotherapy cohorts, respectively (p < 0.001). The number of chemotherapy cycles was similar for chemotherapy given pre- or post-radium-223. Mean line of mCRPC therapy of radium-223 was 3rd and 5th when given pre- and post-chemotherapy, respectively (p < 0.001). 41.8% patients were treated with radium-223 in combination with another mCRPC therapy, commonly abiraterone acetate (43.5%) or enzalutamide (52.2%). The majority received combination therapy for the duration of radium-223 treatment; 20.7% started another agent after radium-223 initiation; 20.7% initiated radium-223 while on established therapy. Median OS from first mCRPC treatment was 39.4 months (95% CI 33.0, 48.8) for patients with radium-223 pre-chemotherapy vs. 37.4 months (95% CI 32.0, 43.5) post-chemotherapy (and 35.2 months [95% CI 27.9, 43.3] vs. 32.0 months [95% CI 26.9, 36.0] for patients with radium-223 combination vs. monotherapy). This retrospective analysis of patients treated with radium-223 demonstrates that administration of radium-223 pre-chemotherapy increased likelihood of completion of radium-223 treatment. Radium-223 given pre- or post-chemotherapy and with or without combination therapy did not result in significant differences in OS. Additional studies are needed to determine the optimal sequencing strategy of mCRPC in the modern era.
登录
查看更多内容
DOI：
10.1056/nejmoa1503747
发表时间：
2015-08-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sweeney CJ;Chen YH;Carducci M;Liu G;Jarrard DF;Eisenberger M;Wong YN;Hahn N;Kohli M;Cooney MM;Dreicer R;Vogelzang NJ;Picus J;Shevrin D;Hussain M;Garcia JA;DiPaola RS
通讯作者：
DiPaola RS
DOI：
10.1007/s00259-019-4261-y
发表时间：
2019-05-01
影响因子：
9.1
作者：
Dizdarevic, Sabina;Petersen, Peter Meidahl;Du, Yong
通讯作者：
Du, Yong
影响因子：
3.2
作者：
Shore, Neal D.;Tutrone, Ronald F.;Harrelson, Stacey S.
通讯作者：
Harrelson, Stacey S.
影响因子：
158.5
作者：
Parker, C.;Nilsson, S.;Sartor, O.
通讯作者：
Sartor, O.
影响因子：
51.1
作者：
Ryan, Charles J.;Smith, Matthew R.;Rathkopf, Dana E.
通讯作者：
Rathkopf, Dana E.